Hemant Surgical Industries began in 1985 as a specialist importer of Japanese wound dressings and dialysis products, and over four decades transformed itself into a manufacturer that now makes, assembles, imports and markets medical equipment and disposables across five therapy areas. The recurring approach is to secure exclusive partnerships with global technology firms, then progressively localise production in its own Indian factories - moving from trading to assembling to full manufacturing - while building the service infrastructure to install and maintain the equipment it sells. # Business segments A single medical-device engine spanning five therapy areas, built on exclusive global partnerships and progressively localised manufacturing, with a growing layer of turnkey hospital-setup services and international dialysis operations. ## 1. Medical devices and disposables: the company's sole engine, from import to factory floor **It sources technology through exclusive partnerships with Japanese, Chinese, Korean and American firms, then assembles or manufactures the products in its own Indian units - selling equipment, consumables and the service contracts to keep them running.** - **Five therapy areas, one portfolio** - the company covers Renal Care, Cardiovascular Disease, Respiratory Disease, Critical Care and Radiology, and Surgical Disposables, with over 90 products registered and accepted by leading hospitals. - **Exclusive partnerships lock in technology** - a 35-year relationship with JMS Co. Ltd., Japan, supplies meditapes and technical know-how for wound dressings; Zone Care, China, provides ECG and ultrasound systems; SWS, China, supplies dialysis machines and consumables; Takagi, Japan, and SonoMed, USA, bring ophthalmic imaging equipment; and a Korean partner provides digital X-ray panels. These agreements give the company preferential access to products it can later localise. - **Three assembly units turn imports into finished goods** - Unit I (operational since 1999) manufactures dialysis solutions, sterilants and purified water; Unit II assembles nebulisers, oxygen concentrators, dialysers, digital thermometers and pulse oximeters under the 'Aero Plus' brand, processes silicone Foley catheters under 'Safecath', and refurbishes dialysis machines; Unit III assembles infusion sets, ECG machines, ultrasound machines, patient monitors and ventilators. - **Localisation is the next step** - a new 100,000 sq ft factory is planned in Shambhaji Nagar, and an advanced facility in AURIC Industrial Smart City, Maharashtra, is nearing completion with Fanuc injection-moulding machines commissioned to achieve 100% local production of JMS Meditape and related consumables. A Semi Knocked Down manufacturing agreement with Sonomed Escalon, USA, brings ophthalmic ultrasound device assembly to India, with a roadmap to full manufacturing. - **Turnkey services make the sale sticky** - the company sets up and maintains dialysis centres, imaging and diagnostic centres, modular ICUs, modular operating theatres, oncology labs, blood banks and dental clinics, supported by a team of biomedical engineers and 24x7 technical assistance. This turns a product sale into an ongoing service relationship. ## 2. International dialysis operations: exporting the service model **The company runs its own dialysis centres abroad and sells medical disposables directly in East Africa, the Philippines and soon the Middle East - taking the same equipment-and-service formula to markets with scarce dialysis capacity.** - **Own centres, not just exports** - a fully operational dialysis centre in Santa Rita, Philippines, generates revenue from patient services, with the company managing the entire system alongside local partners; two additional licensed centres were nearing launch. - **Direct sales offices in four countries** - offices in Uganda, Kenya, Tanzania and the Philippines market medical disposables and equipment directly, bypassing distributors and capturing margin. - **Pipeline markets** - the company is in advanced stages of setting up operations in Dubai and the USA, extending the same dialysis-and-disposables playbook. # Group structure and partners **Two recently acquired subsidiaries extend the company into precision oncology diagnostics and ophthalmic device manufacturing, while a web of exclusive agreements with global equipment makers supplies the technology pipeline.** - **Lifesenz Cancer Research Labs** - acquired in June 2026 as a 66.66% subsidiary, Lifesenz uses patient-derived 3D cancer cell models for ex-vivo chemo-sensitivity analysis, helping clinicians select treatments in precision oncology; the acquisition was a related-party transaction conducted at arm's length. - **Solar Opto-Medic Private Limited** - a wholly-owned subsidiary acquired in March 2025, engaged in healthcare, treatment and diagnosis. - **Sonomed Escalon SKD agreement** - signed March 2026, this gives Hemant Surgical exclusive rights to assemble and distribute two ophthalmic ultrasound device models in India, with a subsequent expansion targeting 100% local manufacturing; the company holds no equity in Sonomed Escalon. - **Foundational partnerships** - JMS Japan and JMS Singapore (35 years), Zone Care (China), SWS (China), Pixxgen and Remedi (Korea), Takagi (Japan), and SonoMed (USA) form the core technology-sourcing network that feeds the company's assembly lines and product pipeline.